CanWell announced today that the preclinical results of its small molecule TLR7 agonist CAN1012 were presented at the 37th Annual Meeting of the Society for Immunotherapy of Tumors (SITC 2022, Boston).
Abstract ID: #1171
Poster title: CAN1012: A SELECTIVE AND POTENT TLR7 AGONIST WITH STRONG ANTITUMORAL PROPERTIES MEDIATED BY LOCALIZED INNATE IMMUNE ACTIVATION
Time: November 8-12, 2022. Boston US
CAN1012 is a slow-release selective TLR7 receptor agonist exclusively developed by CanWell with global intellectual property rights. Preclinical studies have shown that CAN1012 has high selectivity and activities with low toxicities. It continuously stimulates the target immune cells in the tumor microenvironment, releasing a variety of cytokines/chemokines related to drug efficacy, thereby promoting the activation of anti-tumor immune cells and their infiltration into the tumor, transforming the “cold” tumor with a low immune response into a “hot” tumor with a strong immune response. When CAN1012 is used as a single agent in various preclinical tumor models, it has shown robust anti-tumor activities, while exhibiting extremely low systemic exposure. In addition, CAN1012 can be combined with a variety of tumor immune checkpoint inhibitors, targeted therapy drugs or chemotherapy to produce stronger anti-tumor activities.
CAN1012 is currently in clinical Ph I development in China and the United States. In June 2021, it obtained IND approval from the US FDA and entered phase I clinical trial (NCT04987112) in the US. In July 2022, it received IND clearance from the Chinese CDE (JXHL2200119). A multi-center phase I clinical trial is currently ongoing in China.